Bipolar I Disorder
February 26, 2026
Cyclothymic Disorder (Cyclothymia)
February 26, 2026
Overview
Depression or Major depressive disorder (MDD) is characterized by persistent low mood, loss of interest or pleasure in activities, and associated cognitive, behavioral, and physical symptoms that significantly impair functioning. Depression exists on a spectrum from mild to severe and typically follows a recurrent course, with many individuals experiencing multiple episodes throughout their lifetime. MDD is a leading cause of disability worldwide; early recognition and appropriate intervention are essential for optimal outcomes and relapse prevention (NICE, 2022). The blog post provides a clinical overview to improve understanding on MDD disorder ranging from assessment, diagnosis, plan, treatment to resources.
Epidemiology
Prevalence
MDD affects millions globally, with the Global Burden of Disease Study 2021 identifying depressive disorders as a major contributor to years lived with disability (YLDs), particularly among adolescents and young adults. High-income regions report higher diagnosed prevalence, likely reflecting better detection and reporting systems rather than true epidemiological differences. Disability-adjusted life years (DALYs) attributable to depressive disorders have increased over the past three decades (Zhao et al., 2025).Patterns (Sex, Age, Location)
MDD is approximately twice as common in women as in men. Onset typically occurs in early adulthood, though it can present across all age groups. Children and adolescents may present with irritability rather than sadness, while older adults more frequently report somatic complaints and cognitive symptoms. Prevalence varies considerably by geographic region, influenced by socioeconomic factors, healthcare access, and cultural attitudes toward mental health (Zhao et al., 2025; APA, 2019).Determinants
Etiology (Cause):
MDD arises from a complex interplay of biological, psychological, and environmental factors. Neurobiological contributors include dysregulation of monoaminergic neurotransmission (serotonin, norepinephrine, dopamine), HPA axis dysfunction leading to chronic cortisol elevation, and neuroinflammatory processes involving elevated pro-inflammatory cytokines (IL-6, TNF-α). Reduced BDNF levels impair neuroplasticity, contributing to decreased hippocampal volume and compromised mood-regulating circuits (De Menezes Galvão et al., 2021; Mehra et al., 2025).Risk Factors
- Genetic: Heritability estimated at 37–40%; family history significantly increases risk (Mehra et al., 2025).
- Psychological: History of trauma, adverse childhood experiences, maladaptive cognitive patterns, and chronic stress.
- Social: Social isolation, lack of support systems, unemployment, financial hardship
- Medical: Chronic illness, inflammatory conditions, thyroid dysfunction, and certain medications.
- Substance use: Alcohol and substance use disorders are both a risk factor and a common comorbidity.
Effects on Population
Individuals
MDD substantially impairs occupational functioning, interpersonal relationships, and quality of life. It is associated with increased risk of cardiovascular disease, metabolic disorders, and premature mortality. MDD elevates suicide risk, with approximately 15% of individuals with severe depression dying by suicide (Bains & Abdijadid, 2020).Family
Family members experience significant caregiver burden, including emotional distress, financial strain, and disruption to household functioning. Children of parents with MDD carry elevated risk of developing psychiatric disorders themselves.Community
MDD contributes substantially to lost productivity, increased healthcare utilization, and economic burden at the population level. It is one of the leading causes of work disability globally (Zhao et al., 2025).Assessment
Symptom Severity Assessment Tools
Preclinical / Screening
The Patient Health Questionnaire-9 (PHQ-9) is the recommended validated screening tool for depression in primary care and community settings. Scores range from 0–27, with thresholds indicating mild (5–9), moderate (10–14), moderately severe (15–19), and severe (≥20) depression. The Hospital Anxiety and Depression Scale (HADS) is also commonly used, particularly in medical settings (NICE, 2022).Clinical (Mental Status Examination — MSE)
A full MSE should assess appearance, behavior, speech, mood and affect, thought form and content (including suicidal/homicidal ideation), perceptual disturbances, cognition, insight, and judgment. A comprehensive psychiatric history should be gathered, including symptom onset, duration, severity, prior episodes, family history, psychosocial stressors, and medication review. Physical examination and investigations (thyroid function, B12, folate, CBC) are essential to rule out medical causes (NICE, 2022; APA, 2019).Post-Clinical / Monitoring
Repeat PHQ-9 assessments at follow-up visits are recommended to monitor treatment response. A reduction of ≥0 points from baseline, or a score <10, indicates clinically meaningful improvement. Regular reassessment of suicide risk, functional status, and treatment adherence is essential throughout the care episode.Diagnosis
DSM-5-TR Diagnostic Criteria
For a diagnosis of MDD, a patient must experience at least five of the following symptoms during the same two-week period, with at least one being either (1) depressed mood or (2) loss of interest or pleasure (APA, 2022):Criterion A: Symptom Cluster (5 or more, for ≥2 weeks)
- Depressed mood most of the day, nearly every day (in children/adolescents, may be irritable mood).
- Anhedonia — markedly diminished interest or pleasure in all or almost all activities.
- Weight/appetite changes — significant weight loss or gain, or decreased/increased appetite.
- Sleep disturbance — insomnia or hypersomnia.
- Psychomotor changes — observable agitation or retardation.
- Fatigue or loss of energy.
- Worthlessness or excessive guilt (may be delusional).
- Cognitive impairment — diminished ability to think, concentrate, or decide.
- Suicidality — recurrent thoughts of death, suicidal ideation, plan, or attempt.
Criterion B: Functional Impairment
- Symptoms cause clinically significant distress or impairment in social, occupational, or other areas of functioning.
Criterion C: Exclusion of Substance/Medical Cause
- Symptoms are not attributable to the physiological effects of a substance or another medical condition.
Criterion D: Exclusion of Other Psychotic Disorders
- The episode is not better explained by schizoaffective disorder, schizophrenia, or other primary psychotic disorders.
Criterion E: Exclusion of Manic/Hypomanic Episode
- There has never been a manic episode or hypomanic episode (if so, consider bipolar disorder).
Differential Diagnosis
Key conditions to differentiate from MDD (Bains & Abdijadid, 2020; APA, 2022):- Bipolar Disorder: Depressive episodes are clinically indistinguishable from MDD; differentiated by history of manic/hypomanic episodes. Critical distinction — antidepressant monotherapy may precipitate mania.
- Persistent Depressive Disorder (Dysthymia): Chronic low-grade depressive symptoms ≥2 years; typically less severe than MDD but more chronic.
- Adjustment Disorder with Depressed Mood: Occurs in response to an identifiable stressor; typically resolves within 6 months of stressor removal.
- Medical Conditions: Hypothyroidism, anemia, vitamin B12/folate deficiency, and neurological disorders can mimic MDD. Laboratory workup is essential.
- Substance-Induced Mood Disorder: Depression secondary to alcohol, stimulants, or medications (e.g., corticosteroids, beta-blockers).
- Anxiety Disorders: Frequently comorbid with MDD; overlapping symptoms include fatigue, sleep disturbance, and concentration difficulties.
- Grief/Bereavement: Normal grief can be distinguished by preserved capacity for positive affect, absence of sustained worthlessness, and response to social support.
- Psychotic Disorders / Personality Disorders: May present with affective components requiring careful evaluation.
Plan
Treatment Goals
- Achieve full symptom remission (PHQ-9 <5) and restore baseline functioning.
- Prevent relapse and recurrence.
- Enhance quality of life and social/occupational reintegration.
Implementation
Psychopharmacology
First-Line
Selective Serotonin Reuptake Inhibitors (SSRIs): Recommended first-line pharmacological treatment for moderate-to-severe MDD due to their favorable tolerability profile and safety in overdose. Examples include sertraline, escitalopram, and fluoxetine. Antidepressants are not routinely recommended for mild depression unless symptoms persist or the patient has a history of moderate-to-severe episodes. Therapeutic response typically requires 2–4 weeks. Treatment should continue for at least 6 months after remission (NICE, 2022).Second-Line
If the initial SSRI proves inadequate after an adequate trial (typically 4–6 weeks at therapeutic dose), options include: switching to an alternative SSRI or a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI; e.g., venlafaxine, duloxetine), or adding a second agent. Mirtazapine, bupropion, and tricyclic antidepressants (TCAs) are alternatives when SSRIs are not tolerated or contraindicated (NICE, 2022).Third-Line (Treatment-Resistant Depression)
Augmentation strategies for treatment-resistant depression (TRD) include lithium, atypical antipsychotics (e.g., quetiapine, aripiprazole), or combination antidepressant therapy. Ketamine/esketamine (nasal spray) has emerging evidence for rapid-acting antidepressant effects in TRD. Discontinuation of antidepressants should always be gradual to minimize withdrawal symptoms (NICE, 2022; APA, 2019).Psychotherapy
Individual
Cognitive Behavioral Therapy (CBT) is the most extensively evidenced individual therapy for MDD, targeting maladaptive thought patterns and behaviors. Interpersonal Therapy (IPT) addresses relationship difficulties and life transitions contributing to depression. Behavioral Activation increases engagement with rewarding activities to counter withdrawal. For chronic or recurrent depression, Mindfulness-Based Cognitive Therapy (MBCT) is recommended to prevent relapse (NICE, 2022).Group
Group-based CBT programs are recommended for mild-to-moderate depression as accessible, cost-effective interventions. Psychoeducation groups and structured support groups can complement individual therapy and reduce isolation (NICE, 2022).Complementary Care
Nursing
Nurses play a central role in psychoeducation, medication adherence counseling, routine PHQ-9 monitoring, suicide risk screening, and coordination of care across the treatment team.Nutrition
Emerging evidence supports a Mediterranean-style diet for mood regulation. Nutritional deficiencies (B12, folate, vitamin D, omega-3 fatty acids) should be assessed and corrected. Referral to a dietitian is appropriate for patients with significant weight changes or comorbid metabolic conditions.Physical Activity / Physiotherapy
Structured group exercise is strongly endorsed by NICE (2022) for mild-to-moderate depression. Regular aerobic activity demonstrates significant antidepressant effects and should be tailored to individual capabilities to promote sustainable engagement.Social Work
Social workers address psychosocial determinants including housing instability, financial hardship, employment barriers, and social isolation. They facilitate access to community resources and coordinate support services.Occupational Therapy
Occupational therapists support functional recovery by addressing deficits in work, self-care, and leisure activities. They facilitate graded return-to-work programs and identify environmental modifications to support daily functioning.Evaluation
Prognosis
With adequate treatment, most patients achieve symptom remission within several months. However, MDD frequently follows a recurrent course: approximately 50–85% of individuals who experience one episode will have at least one recurrence. One-third develop chronic or treatment-resistant depression. Favorable prognostic factors include strong social support, absence of comorbid substance use, and good treatment adherence. Early onset, severe episodes, psychotic features, and medical comorbidities predict poorer outcomes (Bains & Abdijadid, 2020).Follow-Up
Follow-up should occur within 1–2 weeks of treatment initiation or dose change to monitor response, tolerability, and suicide risk. Reassess with PHQ-9 at 4–8 weeks. Once stable, schedule 3-monthly reviews. Maintenance treatment for at least 6 months post-remission is recommended; patients with recurrent episodes may require 2+ years of maintenance pharmacotherapy (NICE, 2022).Referral
Refer to psychiatry when:- diagnosis is uncertain.
- patient fails two adequate antidepressant trials (Treatment-Resistant Depression).
- significant comorbidities exist (e.g., bipolar disorder, psychotic features, substance use disorder, eating disorder, or personality disorder).
- specialized therapies (ECT, esketamine) are being considered (APA, 2019; NICE, 2022).
Red Flags (Immediate Action Required)
- Suicidal/Homicidal Ideation with Plan or Intent: Emergency referral or inpatient hospitalization required.
- Psychotic Features: Delusions or hallucinations; standard antidepressant monotherapy is insufficient.
- Manic Switching: Pressured speech, impulsivity, decreased sleep need — consider bipolar disorder; stop antidepressant monotherapy.
- Severe Self-Neglect: Inability to maintain nutrition, hydration, or basic hygiene — outpatient care no longer appropriate.
- Rapid Deterioration: Any sudden worsening despite treatment warrants urgent reassessment.
Resources
-
Crisis Support:
- National Suicide Prevention Lifeline: Call or text 988 (US, 24/7).
- Crisis Text Line: Text “HELLO” to 741741.
- International resources: https://www.iasp.info/resources/Crisis_Centres/.
- If experiencing a mental health emergency: call 988 (US), attend nearest emergency department, or contact local emergency services.
References
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787 American Psychological Association. (2019). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf Bains, N., & Abdijadid, S. (2020). Major depressive disorder. StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK559078 De Menezes Galvão, A. C., et al. (2021). Pathophysiology of major depression by clinical stages. Frontiers in Psychology, 12, 641779. https://doi.org/10.3389/fpsyg.2021.641779 Mehra, A., Khanna, J., Singh, G., Sachdeva, V., & Bedi, N. (2025). A comprehensive review on major depressive disorder: Exploring etiology, pathogenesis and clinical approaches. Current Behavioral Neuroscience Reports, 12(1), 18. https://doi.org/10.1007/s40473-025-00308-y National Institute for Health and Care Excellence (NICE). (2022). Depression in adults: Treatment and management. https://www.ncbi.nlm.nih.gov/books/NBK583074/ Zhao, L., Lou, Y., Tao, Y., Wang, H., & Xu, N. (2025). Global, regional and national burden of depressive disorders in adolescents and young adults, 1990–2021. Frontiers in Public Health, 13, 1599602. https://doi.org/10.3389/fpubh.2025.1599602
